Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib dose-ranging trial in adults with nonsegmental vitiligo
2025-522309-40-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in nonsegmental vitiligo comparing Zasocitinib dose-ranging arm(s) with Placebo (2 arms). Primary endpoint: Proportion of participants achieving at least 75% improvement from baseline in F-VASI at Week 24. Planned start Feb 2026; status: authorised.
02
Drugs
zasocitinib
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on 2025-522309-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522309-40-00.